BHVN - Save Yourself the Migraine and Buy This 1 Pharma Stock Now
Biohaven Pharmaceuticals (NYSE: BHVN) expects to announce results from its phase 3 clinical trials before the end of 2019. The company seeks to develop drugs to treat diseases of the brain, a notoriously challenging area for drug developers. However, the risk-reward ratio should be attractive to investors.
Image source: Getty Images.
One of Biohaven's key research and development efforts centers on the development of drugs that interact with the calcitonin gene-related peptide (CGRP) receptor, which is found in a pathway that sends pain signals to the brain. The company has two drugs targeting the CGRP receptor that are meant to treat and prevent migraines.